» Articles » PMID: 20022440

Novel Approaches Using Alkaline or Acid/guanidine Treatment to Eliminate Therapeutic Antibody Interference in the Measurement of Total Target Ligand

Overview
Specialty Chemistry
Date 2009 Dec 22
PMID 20022440
Citations 8
Authors
Affiliations
Soon will be listed here.
Abstract

Measurement of the total target ligand can help to provide pharmacokinetic (PK) and pharmacodynamic (PD) informations. However, the presence of monocloncal antibody therapeutics (ThAs) interferes with ELISA determinations of the total target proteins. The interferences can cause over- or under-estimation of the target protein analysis. The nature of interferences was dependent upon the ThA, target protein, antibody reagents and assay conditions of the ELISA. We have developed novel alkaline and acid/guanidine treatment approaches to dissociate the protein binding and preferentially denature the ThA. The neutralized target proteins can be determined by ELISA. These methods provide reproducible measurements of total target protein without ThA interference. Serum samples, standards and QCs containing target protein and ThA were treated with alkaline buffer (pH>13) containing casein or acid/guanidine buffer (pH<1). Total target proteins for two different ThA systems were successfully measured and interferences were completely eliminated by the treatments. These methods were successfully applied to analysis in pre-clinical serum samples.

Citing Articles

The impact of immunogenicity on therapeutic antibody pharmacokinetics: A preclinical evaluation of the effect of immune complex formation and antibody effector function on clearance.

Opolka-Hoffmann E, Jordan G, Otteneder M, Kieferle R, Lechmann M, Winter G MAbs. 2021; 13(1):1995929.

PMID: 34763611 PMC: 8726625. DOI: 10.1080/19420862.2021.1995929.


Interrelationships between Infliximab and Recombinant Tumor Necrosis Factor- in Plasma Using Minimal Physiologically Based Pharmacokinetic Models.

Chen X, DuBois D, Almon R, Jusko W Drug Metab Dispos. 2017; 45(7):790-797.

PMID: 28411280 PMC: 5478907. DOI: 10.1124/dmd.116.074807.


Unraveling the Effect of Immunogenicity on the PK/PD, Efficacy, and Safety of Therapeutic Proteins.

Smith A, Manoli H, Jaw S, Frutoz K, Epstein A, Khawli L J Immunol Res. 2016; 2016:2342187.

PMID: 27579329 PMC: 4992793. DOI: 10.1155/2016/2342187.


A white paper--consensus and recommendations of a global harmonization team on assessing the impact of immunogenicity on pharmacokinetic measurements.

Sailstad J, Amaravadi L, Clements-Egan A, Gorovits B, Myler H, Pillutla R AAPS J. 2014; 16(3):488-98.

PMID: 24682765 PMC: 4012055. DOI: 10.1208/s12248-014-9582-y.


Theoretical considerations and practical approaches to address the effect of anti-drug antibody (ADA) on quantification of biotherapeutics in circulation.

Kelley M, Ahene A, Gorovits B, Kamerud J, King L, McIntosh T AAPS J. 2013; 15(3):646-58.

PMID: 23543601 PMC: 3691419. DOI: 10.1208/s12248-013-9468-4.